Page: Tafamidis soft gelatin capsules 20 mg and 61 mg product-specific bioequivalence guidance-2026/4/30

Document: List of centrally authorised products with safety-related changes to the product information-2026/4/30

Document: New product information wording: extracts from PRAC recommendations on signals adopted at the 12-15 January 2026 PRAC-2026/4/29

Page: Class III implantable devices and Class IIb medical devices intended to administer or remove medicinal products: expert panel opinions-2026/4/29

Document: European Shortages Monitoring Platform (ESMP) User guide for national competent authorities-2026/4/29

Page: VICH GL18(R2) impurities: residual solvents in new veterinary medicinal products, active substances and excipients - Scientific guideline-2026/4/29

Page: ICH Q3C (R9) Residual solvents - Scientific guideline-2026/4/29

Document: Annexes to ICH Q3C guideline on impurities: guideline for residual solvents (EMA/CHMP/ICH/82260/2006) and VICH GL18 Impurities: residual solvents in new veterinary medicinal products, active substances and excipients (EMA/CVMP/VICH/502/1999) - R

Page: Advisory group on vaccine confidence-2026/4/29

Document: Vaccine confidence advisory group: Terms of reference-2026/4/29